KPIs & Operating Metrics(New)
Advance Purchase Agreements (Apas)Breakdown Of AssetsCollabration Revenue By CategoryCollabration Revenue By Category AnnualCost Of SalesDeferred Revenue By SegmentDoses DeliveredEmployee StatisticsGrant Revenue By Category AnnualGrant Revenue By CategoyGross Margin %Gross ProfitIncome (Loss) Before Income Tax By RegionManufacturing Technology Center (Mtc)Operating Expense As A % Of Total Revenue %Operating Expense SegregationProduct Revenue By Geography %Product Revenue By Geography Annual %Product Sales By GeographyProduct Sales By Geography AnnualProfitabilityProfitability %Profitability AnnualProfitability Annual %Property And Equipment BreakdownProperty And Equipment By GeographyPurchase CommitmentsRemaining Performance ObligationRemaining Performance ObligationsRevenue By Major CustomersRevenue By Major Customers %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Contractual Obligations AnnualTotal Deferred Revenue
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Moderna (MRNA) Gross Profit (2021 - 2025)

Moderna (MRNA) has disclosed Gross Profit for 7 consecutive years, with -$566.0 million as the latest value for Q1 2026.

  • For Q1 2026, Gross Profit fell 3244.44% year-over-year to -$566.0 million; the TTM value through Mar 2026 reached $492.0 million, down 70.25%, while the annual FY2025 figure was $1.1 billion, 39.28% down from the prior year.
  • Gross Profit hit -$566.0 million in Q1 2026 for Moderna, down from $226.0 million in the prior quarter.
  • Across five years, Gross Profit topped out at $5.0 billion in Q1 2022 and bottomed at -$566.0 million in Q1 2026.
  • Average Gross Profit over 5 years is $1.2 billion, with a median of $227.0 million recorded in 2024.
  • Year-over-year, Gross Profit skyrocketed 428.78% in 2024 and then plummeted 3244.44% in 2026.
  • Moderna's Gross Profit stood at $4.7 billion in 2022, then tumbled by 59.82% to $1.9 billion in 2023, then plummeted by 87.94% to $227.0 million in 2024, then fell by 0.44% to $226.0 million in 2025, then tumbled by 350.44% to -$566.0 million in 2026.
  • According to Business Quant data, Gross Profit over the past three periods came in at -$566.0 million, $226.0 million, and $809.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.